Find out how and why mathematics is used in microeconomics, its limitations, and the math skills that economics students need.

Share on Pinterest According to research, most people may not be getting enough omega-3 fatty acids in their diet. Image Credit: Tanja Ivanova/Getty Images A new research review reports that most ...

ORLANDO, Fla., Dec. 9, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ), the worldwide leader in multiple myeloma, today announced new data from the investigational Phase 3 MajesTEC-3 study that ...

New results from a study of a drug called Gazyva (obinutuzumab) showed that it significantly reduced disease activity in adults with systemic lupus erythematosus (SLE). The drug was developed by ...

HONG KONG, Oct. 16, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) today announced that the groundbreaking results from the registrational Phase III AK112-306/HARMONi-6 study of ivonescimab have been ...

Contact: Chris Martin, MPH IASLC Media Relations [email protected] (Barcelona, Spain September 7, 2025, 10:45 a.m. CEST / UTC +2) – New results from the ACROSS 2 Phase III trial demonstrate ...

Data from the late-stage MAPLE-HCM study position Cytokinetics’ cardiac myosin inhibitor aficamten as a potential first-line therapy for patients with obstructive hypertrophic cardiomyopathy.

Pfizer’s sickle cell disease (SCD) drug has flunked a key phase 3 test, the latest blow to the pharma’s $5.4 billion acquisition of Global Blood Therapeutics. Pfizer acquired the P-selectin inhibitor, ...

Please provide your email address to receive an email when new articles are posted on . Gildeuretinol helped patients maintain visual acuity for up to 7 years. The oral therapy was well tolerated.

Pharvaris, a late-stage biopharmaceutical company focused on developing oral bradykinin B2 receptor antagonists for bradykinin-mediated diseases like hereditary angioedema (HAE), has updated the ...

Otsuka Pharmaceutical has shared more detailed data behind its kidney disease drug’s phase 3 win, showing the monoclonal antibody halved patients’ urine protein-to-creatinine ratio (UPCR) levels.